Skip to main content

Mintz Advises Viela Bio in Spin Out of Medimmune

Company Launches with Up to $250 Million Series A Financing

Viela Bio announced that today it has incorporated as an independent inflammation- and autoimmunity-focused biotechnology company after spinning out six molecules from MedImmune, the global biologics research and development arm of AstraZeneca. Mintz served as Viela’s legal counsel. For more information on this deal, please click here.